A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs.


Updates from The Motley Fool

Latest updates on Momenta Pharmaceuticals from Fool.com.  The Fool has written over 100 articles on Momenta Pharmaceuticals.
Momenta Moves On

The biotech is shifting focus away from biosimilars and toward its pipeline of immune drugs.

Momenta Moves Meticulously

Investors continue to wait for the outcome of the biotech's strategic review.



Stock Performance

View Interactive MNTA Charts
Sponsored by

Key Data Points

Primary metrics and data points about Momenta Pharmaceuticals.
Current Price: $11.18
Prev Close: $11.97
Open: $11.95
Bid: $11.10
Ask: $13.00
Day's Range: $11.16 - $12.08
52wk Range: $10.10 - $32.20
Volume: 910,075
Avg Vol 872,127
Market Cap: $854M
P/E (ttm): -5.99
EPS (ttm): -$2.00
Div & Yield: $0.00 (0.0%)

CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Craig A. Wheeler, CEO

76% Approve

Based on 24 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Momenta Pharmaceuticals.

A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers